NYSE: IMAXImax Corp Stock
$27.66+0.61 (+2.26%)
Updated Aug 25, 2025
IMAX Price
$27.66
Fair Value Price
N/A
Market Cap
$1.49B
52 Week Low
$18.76
52 Week High
$29.66
P/E
45.34x
P/B
4.64x
P/S
4.15x
PEG
1.67x
Dividend Yield
N/A
Revenue
$362.48M
Earnings
$32.78M
Gross Margin
56.9%
Operating Margin
14.54%
Profit Margin
9%
Debt to Equity
1.45
Operating Cash Flow
$77M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMAX Overview
IMAX Corporation offers cinematic solutions through proprietary software, theater architecture, intellectual property, and specialized equipment. Its specific offerings include IMAX Digital Re-Mastering, a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens, IMAX theater systems to exhibitor customers through sales, leases, and joint revenue sharing arrangements, and digital projection systems. IMAX was founded in 1967 and is headquartered in Mississauga, Ontario, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMAX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important IMAX news, forecast changes, insider trades & much more!
IMAX News
Overview
Due Diligence Score
–
Industry Average (22)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMAX ($27.66) is trading above its intrinsic value of $9.56, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMAX is poor value based on its earnings relative to its share price (45.34x), compared to the US market average (35.53x)
P/E vs Market Valuation
IMAX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more IMAX due diligence checks available for Premium users.
Valuation
IMAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
45.34x
Industry
17.38x
Market
35.53x
IMAX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
IMAX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
IMAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.64x
Industry
4.05x
IMAX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMAX price to earnings growth (PEG)
For valuing profitable companies with growth potential
IMAX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
IMAX's financial health
Profit margin
Revenue
$91.7M
Net Income
$11.3M
Profit Margin
12.3%
IMAX's Earnings (EBIT) of $52.69M... subscribe to Premium to read more.
Interest Coverage Financials
IMAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$868.6M
Liabilities
$463.5M
Debt to equity
1.45
IMAX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$23.2M
Investing
-$7.4M
Financing
-$3.8M
IMAX's operating cash flow ($76.95M)... subscribe to Premium to read more.
Debt Coverage Financials
IMAX vs Entertainment Stocks
Imax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.